Cargando…

Quinolone Allergy

Quinolones are the second most common antibiotic class associated with drug-induced allergic reactions, but data on quinolone allergy are scarce. This review article discusses the available evidence on quinolone allergy, including prevalence, risk factors, diagnosis, clinical manifestations, cross-r...

Descripción completa

Detalles Bibliográficos
Autores principales: McGee, Edoabasi U., Samuel, Essie, Boronea, Bernadett, Dillard, Nakoasha, Milby, Madison N., Lewis, Susan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789783/
https://www.ncbi.nlm.nih.gov/pubmed/31330937
http://dx.doi.org/10.3390/pharmacy7030097
_version_ 1783458693697765376
author McGee, Edoabasi U.
Samuel, Essie
Boronea, Bernadett
Dillard, Nakoasha
Milby, Madison N.
Lewis, Susan J.
author_facet McGee, Edoabasi U.
Samuel, Essie
Boronea, Bernadett
Dillard, Nakoasha
Milby, Madison N.
Lewis, Susan J.
author_sort McGee, Edoabasi U.
collection PubMed
description Quinolones are the second most common antibiotic class associated with drug-induced allergic reactions, but data on quinolone allergy are scarce. This review article discusses the available evidence on quinolone allergy, including prevalence, risk factors, diagnosis, clinical manifestations, cross-reactivity, and management of allergic reactions. Although the incidence of quinolone allergy is still lower than beta-lactams, it has been increasingly reported in recent decades, most likely from its expanded use and the introduction of moxifloxacin. Thorough patient history remains essential in the evaluation of quinolone allergy. Many diagnostic tools have been investigated, but skin tests can yield false-positive results and in vitro tests have not been validated. The drug provocation test is considered the test of choice to confirm a quinolone allergy but is not without risk. Evidence regarding cross-reactivity among the quinolones is limited and conflicting. Quinolone allergy can be manifested either as an immediate or delayed reaction, but is not uniform across the class, with moxifloxacin posing the highest risk of anaphylaxis. Quinolone should be discontinued when an allergic reaction occurs and avoided in future scenarios, but desensitization may be warranted if no alternatives are available.
format Online
Article
Text
id pubmed-6789783
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67897832019-10-16 Quinolone Allergy McGee, Edoabasi U. Samuel, Essie Boronea, Bernadett Dillard, Nakoasha Milby, Madison N. Lewis, Susan J. Pharmacy (Basel) Review Quinolones are the second most common antibiotic class associated with drug-induced allergic reactions, but data on quinolone allergy are scarce. This review article discusses the available evidence on quinolone allergy, including prevalence, risk factors, diagnosis, clinical manifestations, cross-reactivity, and management of allergic reactions. Although the incidence of quinolone allergy is still lower than beta-lactams, it has been increasingly reported in recent decades, most likely from its expanded use and the introduction of moxifloxacin. Thorough patient history remains essential in the evaluation of quinolone allergy. Many diagnostic tools have been investigated, but skin tests can yield false-positive results and in vitro tests have not been validated. The drug provocation test is considered the test of choice to confirm a quinolone allergy but is not without risk. Evidence regarding cross-reactivity among the quinolones is limited and conflicting. Quinolone allergy can be manifested either as an immediate or delayed reaction, but is not uniform across the class, with moxifloxacin posing the highest risk of anaphylaxis. Quinolone should be discontinued when an allergic reaction occurs and avoided in future scenarios, but desensitization may be warranted if no alternatives are available. MDPI 2019-07-19 /pmc/articles/PMC6789783/ /pubmed/31330937 http://dx.doi.org/10.3390/pharmacy7030097 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
McGee, Edoabasi U.
Samuel, Essie
Boronea, Bernadett
Dillard, Nakoasha
Milby, Madison N.
Lewis, Susan J.
Quinolone Allergy
title Quinolone Allergy
title_full Quinolone Allergy
title_fullStr Quinolone Allergy
title_full_unstemmed Quinolone Allergy
title_short Quinolone Allergy
title_sort quinolone allergy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789783/
https://www.ncbi.nlm.nih.gov/pubmed/31330937
http://dx.doi.org/10.3390/pharmacy7030097
work_keys_str_mv AT mcgeeedoabasiu quinoloneallergy
AT samuelessie quinoloneallergy
AT boroneabernadett quinoloneallergy
AT dillardnakoasha quinoloneallergy
AT milbymadisonn quinoloneallergy
AT lewissusanj quinoloneallergy